273 related articles for article (PubMed ID: 35654820)
1. Maintenance therapy for acute lymphoblastic leukemia: basic science and clinical translations.
Toksvang LN; Lee SHR; Yang JJ; Schmiegelow K
Leukemia; 2022 Jul; 36(7):1749-1758. PubMed ID: 35654820
[TBL] [Abstract][Full Text] [Related]
2. Thiopurine Enhanced ALL Maintenance (TEAM): study protocol for a randomized study to evaluate the improvement in disease-free survival by adding very low dose 6-thioguanine to 6-mercaptopurine/methotrexate-based maintenance therapy in pediatric and adult patients (0-45 years) with newly diagnosed B-cell precursor or T-cell acute lymphoblastic leukemia treated according to the intermediate risk-high group of the ALLTogether1 protocol.
Toksvang LN; Als-Nielsen B; Bacon C; Bertasiute R; Duarte X; Escherich G; Helgadottir EA; Johannsdottir IR; Jónsson ÓG; Kozlowski P; Langenskjöld C; Lepik K; Niinimäki R; Overgaard UM; Punab M; Räty R; Segers H; van der Sluis I; Smith OP; Strullu M; Vaitkevičienė G; Wik HS; Heyman M; Schmiegelow K
BMC Cancer; 2022 May; 22(1):483. PubMed ID: 35501736
[TBL] [Abstract][Full Text] [Related]
3. Myelotoxicity after high-dose methotrexate in childhood acute leukemia is influenced by 6-mercaptopurine dosing but not by intermediate thiopurine methyltransferase activity.
Levinsen M; Rosthøj S; Nygaard U; Heldrup J; Harila-Saari A; Jonsson OG; Bechensteen AG; Abrahamsson J; Lausen B; Frandsen TL; Weinshilboum RM; Schmiegelow K
Cancer Chemother Pharmacol; 2015 Jan; 75(1):59-66. PubMed ID: 25347948
[TBL] [Abstract][Full Text] [Related]
4. Intensification of mercaptopurine/methotrexate maintenance chemotherapy may increase the risk of relapse for some children with acute lymphoblastic leukemia.
Schmiegelow K; Björk O; Glomstein A; Gustafsson G; Keiding N; Kristinsson J; Mäkipernaa A; Rosthøj S; Szumlanski C; Sørensen TM; Weinshilboum R
J Clin Oncol; 2003 Apr; 21(7):1332-9. PubMed ID: 12663723
[TBL] [Abstract][Full Text] [Related]
5. Differential role of thiopurine methyltransferase in the cytotoxic effects of 6-mercaptopurine and 6-thioguanine on human leukemia cells.
Karim H; Ghalali A; Lafolie P; Vitols S; Fotoohi AK
Biochem Biophys Res Commun; 2013 Jul; 437(2):280-6. PubMed ID: 23811272
[TBL] [Abstract][Full Text] [Related]
6. Additive effects of TPMT and NUDT15 on thiopurine toxicity in children with acute lymphoblastic leukemia across multiethnic populations.
Maillard M; Nishii R; Yang W; Hoshitsuki K; Chepyala D; Lee SHR; Nguyen JQ; Relling MV; Crews KR; Leggas M; Singh M; Suang JLY; Yeoh AEJ; Jeha S; Inaba H; Pui CH; Karol SE; Trehan A; Bhatia P; Antillon Klussmann FG; Bhojwani D; Haidar CE; Yang JJ
J Natl Cancer Inst; 2024 May; 116(5):702-710. PubMed ID: 38230823
[TBL] [Abstract][Full Text] [Related]
7. Role of TPMT and ITPA variants in mercaptopurine disposition.
Gerbek T; Ebbesen M; Nersting J; Frandsen TL; Appell ML; Schmiegelow K
Cancer Chemother Pharmacol; 2018 Mar; 81(3):579-586. PubMed ID: 29387964
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics of 6-Thioguanine and 6-Mercaptopurine Combination Maintenance Therapy of Childhood ALL: Hypothesis and Case Report.
Nielsen SN; Frandsen TL; Nersting J; Hjalgrim LL; Schmiegelow K
J Pediatr Hematol Oncol; 2015 Apr; 37(3):e206-9. PubMed ID: 25171455
[TBL] [Abstract][Full Text] [Related]
9. Increments in DNA-thioguanine level during thiopurine-enhanced maintenance therapy of acute lymphoblastic leukemia.
Larsen RH; Utke Rank C; Grell K; Nørgaard Møller L; Malthe Overgaard U; Kampmann P; Nersting J; Degn M; Nygaard Nielsen S; Holst H; Klug Albertsen B; Skov Wehner P; Thude Callesen M; Kanerva J; Leth Frandsen T; Als-Nielsen B; Lyngsie Hjalgrim L; Schmiegelow K
Haematologica; 2021 Nov; 106(11):2824-2833. PubMed ID: 34047177
[TBL] [Abstract][Full Text] [Related]
10. Thiopurine drugs in the treatment of childhood leukaemia: the influence of inherited thiopurine methyltransferase activity on drug metabolism and cytotoxicity.
Lennard L; Welch JC; Lilleyman JS
Br J Clin Pharmacol; 1997 Nov; 44(5):455-61. PubMed ID: 9384462
[TBL] [Abstract][Full Text] [Related]
11. No association between relapse hazard and thiopurine methyltransferase geno- or phenotypes in non-high risk acute lymphoblastic leukemia: a NOPHO ALL2008 sub-study.
Nielsen SN; Toksvang LN; Grell K; Nersting J; Abrahamsson J; Lund B; Kanerva J; Jónsson ÓG; Vaitkeviciene G; Pruunsild K; Appell ML; Hjalgrim LL; Schmiegelow K
Cancer Chemother Pharmacol; 2021 Aug; 88(2):271-279. PubMed ID: 33928426
[TBL] [Abstract][Full Text] [Related]
12. S-adenosylmethionine regulates thiopurine methyltransferase activity and decreases 6-mercaptopurine cytotoxicity in MOLT lymphoblasts.
Milek M; Karas Kuzelicki N; Smid A; Mlinaric-Rascan I
Biochem Pharmacol; 2009 Jun; 77(12):1845-53. PubMed ID: 19428339
[TBL] [Abstract][Full Text] [Related]
13. Optimizing thiopurine therapy in children with acute lymphoblastic leukemia: A promising "MINT" sequencing strategy and therapeutic "DNA-TG" monitoring.
Guo HL; Zhao YT; Wang WJ; Dong N; Hu YH; Zhang YY; Chen F; Zhou L; Li T
Front Pharmacol; 2022; 13():941182. PubMed ID: 36238550
[TBL] [Abstract][Full Text] [Related]
14. The effects of inherited NUDT15 polymorphisms on thiopurine active metabolites in Japanese children with acute lymphoblastic leukemia.
Moriyama T; Nishii R; Lin TN; Kihira K; Toyoda H; Jacob N; Kato M; Koh K; Inaba H; Manabe A; Schmiegelow K; Yang JJ; Hori H
Pharmacogenet Genomics; 2017 Jun; 27(6):236-239. PubMed ID: 28445187
[TBL] [Abstract][Full Text] [Related]
15. The Role of TPMT, ITPA, and NUDT15 Variants during Mercaptopurine Treatment of Swedish Pediatric Patients with Acute Lymphoblastic Leukemia.
Wahlund M; Nilsson A; Kahlin AZ; Broliden K; Myrberg IH; Appell ML; Berggren A
J Pediatr; 2020 Jan; 216():150-157.e1. PubMed ID: 31635813
[TBL] [Abstract][Full Text] [Related]
16. NUDT15 and TPMT genetic polymorphisms are related to 6-mercaptopurine intolerance in children treated for acute lymphoblastic leukemia at the Children's Cancer Center of Lebanon.
Zgheib NK; Akika R; Mahfouz R; Aridi CA; Ghanem KM; Saab R; Abboud MR; Tarek N; El Solh H; Muwakkit SA
Pediatr Blood Cancer; 2017 Jan; 64(1):146-150. PubMed ID: 27577869
[TBL] [Abstract][Full Text] [Related]
17. Understanding thiopurine methyltransferase polymorphisms for the targeted treatment of hematologic malignancies.
Franca R; Braidotti S; Stocco G; Decorti G
Expert Opin Drug Metab Toxicol; 2021 Oct; 17(10):1187-1198. PubMed ID: 34452592
[TBL] [Abstract][Full Text] [Related]
18. Thiopurine Methyltransferase Intermediate Metabolizer Status and Thiopurine-Associated Toxicity During Maintenance Therapy in Childhood Acute Lymphoblastic Leukemia.
Schwarz UI; Woldanski-Travaglini M; Swanston V; Mikhail M; Cacciotti C; Cairney E; Patel S; Seelisch J; Tole S; Wilejto M; Tirona RG; Kim RB; Zorzi AP
Clin Pharmacol Ther; 2023 Jun; 113(6):1326-1336. PubMed ID: 36932910
[TBL] [Abstract][Full Text] [Related]
19. Is 6-thioguanine more appropriate than 6-mercaptopurine for children with acute lymphoblastic leukaemia?
Lennard L; Davies HA; Lilleyman JS
Br J Cancer; 1993 Jul; 68(1):186-90. PubMed ID: 8318412
[TBL] [Abstract][Full Text] [Related]
20. Thiopurine methyltransferase genotype-phenotype discordance and thiopurine active metabolite formation in childhood acute lymphoblastic leukaemia.
Lennard L; Cartwright CS; Wade R; Richards SM; Vora A
Br J Clin Pharmacol; 2013 Jul; 76(1):125-36. PubMed ID: 23252716
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
